Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Free Cash Flow: 2019-2025

Historic Free Cash Flow for Avidity Biosciences (RNA) over the last 6 years, with Sep 2025 value amounting to -$156.9 million.

  • Avidity Biosciences' Free Cash Flow fell 133.05% to -$156.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$592.3 million, marking a year-over-year decrease of 214.18%. This contributed to the annual value of -$307.9 million for FY2024, which is 149.76% down from last year.
  • According to the latest figures from Q3 2025, Avidity Biosciences' Free Cash Flow is -$156.9 million, which was up 22.72% from -$203.0 million recorded in Q2 2025.
  • In the past 5 years, Avidity Biosciences' Free Cash Flow registered a high of $15.6 million during Q4 2023, and its lowest value of -$203.0 million during Q2 2025.
  • For the 3-year period, Avidity Biosciences' Free Cash Flow averaged around -$83.6 million, with its median value being -$67.3 million (2024).
  • Its Free Cash Flow has fluctuated over the past 5 years, first skyrocketed by 139.06% in 2023, then crashed by 763.68% in 2024.
  • Quarterly analysis of 5 years shows Avidity Biosciences' Free Cash Flow stood at -$27.9 million in 2021, then tumbled by 43.40% to -$40.0 million in 2022, then spiked by 139.06% to $15.6 million in 2023, then crashed by 763.68% to -$103.8 million in 2024, then crashed by 133.05% to -$156.9 million in 2025.
  • Its Free Cash Flow was -$156.9 million in Q3 2025, compared to -$203.0 million in Q2 2025 and -$128.6 million in Q1 2025.